{"parse":{"title":"Vitreomacular adhesion","pageid":37204201,"revid":735096947,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em\"><tbody><tr><th colspan=\"2\" style=\"text-align:center;font-size:125%;font-weight:bold;background:#ccc\">Vitreomacular adhesion</th></tr><tr><td colspan=\"2\" style=\"text-align:center\">\n<a href=\"/wiki/File:Schematic_diagram_of_the_human_eye_en.svg\" class=\"image\"><img alt=\"Schematic diagram of the human eye en.svg\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Schematic_diagram_of_the_human_eye_en.svg/300px-Schematic_diagram_of_the_human_eye_en.svg.png\" width=\"300\" height=\"305\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Schematic_diagram_of_the_human_eye_en.svg/450px-Schematic_diagram_of_the_human_eye_en.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Schematic_diagram_of_the_human_eye_en.svg/600px-Schematic_diagram_of_the_human_eye_en.svg.png 2x\" data-file-width=\"416\" data-file-height=\"423\" /></a></td></tr><tr><td colspan=\"2\" style=\"text-align:center\">\nSchematic diagram of the human eye.</td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#eee;;\">Classification and external resources</th></tr><tr><th scope=\"row\"><a href=\"/wiki/Diseases_Database\" title=\"Diseases Database\">DiseasesDB</a></th><td>\n<a rel=\"nofollow\" class=\"external text\" href=\"http://www.diseasesdatabase.com/ddb35117.htm\">35117</a></td></tr><tr class=\"noprint\"><td colspan=\"2\" style=\"text-align:center\">\n<div style=\"text-align: right; font-size:0.9em;\">[<a href=\"https://www.wikidata.org/wiki/Q7937230\" class=\"extiw\" title=\"d:Q7937230\">edit on Wikidata</a>]</div></td></tr></tbody></table>\n<p><b>Vitreomacular adhesion (VMA)</b> is a <a href=\"/wiki/Human\" title=\"Human\">human</a> <a href=\"/wiki/Medical_condition\" class=\"mw-redirect\" title=\"Medical condition\">medical condition</a> where the <a href=\"/wiki/Vitreous_humour\" class=\"mw-redirect\" title=\"Vitreous humour\">vitreous gel</a> (or simply vitreous) of the <a href=\"/wiki/Human_eye\" title=\"Human eye\">human eye</a> adheres to the <a href=\"/wiki/Retina\" title=\"Retina\">retina</a> in an abnormally strong manner. As the eye ages, it is common for the vitreous to separate from the retina. But if this separation is not complete, i.e. there is still an <b>adhesion</b>, this can create pulling forces on the retina that may result in subsequent loss or distortion of vision. The adhesion in of itself is not dangerous, but the resulting pathological <a href=\"/w/index.php?title=Vitreomacular_traction&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Vitreomacular traction (page does not exist)\">vitreomacular traction</a> (VMT) can cause severe ocular damage.  \n</p><p>The current <a href=\"/wiki/Standard_of_care\" title=\"Standard of care\">standard of care</a> for treating these adhesions is <a href=\"/wiki/Vitrectomy\" title=\"Vitrectomy\">pars plana vitrectomy</a> (PPV), which involves surgically removing the vitreous from the eye. A biological agent for non-invasive treatment of adhesions called <a href=\"/wiki/Ocriplasmin\" title=\"Ocriplasmin\">ocriplasmin</a> has been approved by the FDA  on Oct 17 2012.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Pathology\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Pathology</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Symptomatic_VMA\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Symptomatic VMA</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Diagnosis_and_Treatment_of_Symptomatic_VMA\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Diagnosis and Treatment of Symptomatic VMA</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Pathology\">Pathology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Vitreomacular_adhesion&amp;action=edit&amp;section=1\" title=\"Edit section: Pathology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Over time, it is common for the vitreous within the human eye to <a href=\"/wiki/Liquify\" class=\"mw-redirect\" title=\"Liquify\">liquify</a> and collapse in processes known as <a href=\"/wiki/Syneresis_(chemistry)\" title=\"Syneresis (chemistry)\">syneresis</a> and <a href=\"/w/index.php?title=Synchisis&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Synchisis (page does not exist)\">synchisis</a> respectively. This creates fluid-filled areas that can combine to form pockets of vitreous gel that are mostly liquid with very small concentrations of <a href=\"/wiki/Collagen\" title=\"Collagen\">collagen</a>. If these liquid pockets are close enough to the interface between the vitreous gel and the retina, they can cause complete separation of the vitreous from the retina in a normally occurring process in older humans called <a href=\"/wiki/Posterior_vitreous_detachment\" title=\"Posterior vitreous detachment\">posterior vitreous detachment</a> (PVD). PVD in of itself is not dangerous and a natural process. \n</p><p>If the separation of the vitreous from the retina is not complete, areas of focal attachment or adhesions can occur, i.e. a VMA. The pulling forces or traction from this adhesion on the retinal surface can sometimes cause <a href=\"/wiki/Edema\" title=\"Edema\">edema</a> within the retina, damage to retinal blood vessels causing <a href=\"/wiki/Bleeding\" title=\"Bleeding\">bleeding</a>, or damage to the <a href=\"/wiki/Optic_nerve\" title=\"Optic nerve\">optic nerve</a> causing disruption in the <a href=\"/wiki/Nerve_signal\" class=\"mw-redirect\" title=\"Nerve signal\">nerve signals</a> sent to the <a href=\"/wiki/Brain\" title=\"Brain\">brain</a> for <a href=\"/wiki/Visual_processing\" title=\"Visual processing\">visual processing</a>. It is important to note that while the VMA itself is not dangerous, the resultant pulling on the retina called vitreomacular traction (VMT) causes the above damage. The size and strength of the VMA determine the variety of resulting <a href=\"/wiki/Pathologies\" class=\"mw-redirect\" title=\"Pathologies\">pathologies</a> or symptoms.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup>\n</p><p>VMA can also lead to the development of VMT/traction-related complications such as <a href=\"/wiki/Macular_pucker\" class=\"mw-redirect\" title=\"Macular pucker\">macular puckers</a> and <a href=\"/wiki/Macular_hole\" title=\"Macular hole\">macular holes</a> leading to <a href=\"/wiki/Distorted_vision\" title=\"Distorted vision\">distorted vision</a> or <a href=\"/wiki/Metamorphopsia\" title=\"Metamorphopsia\">metamorphopsia</a>; <a href=\"/wiki/Epiretinal_membrane\" title=\"Epiretinal membrane\">epiretinal membrane</a>; <a href=\"/w/index.php?title=Tractional_macular_oedema&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Tractional macular oedema (page does not exist)\">tractional macular oedema</a>; <a href=\"/w/index.php?title=Myopic_macular_retinoschisis&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Myopic macular retinoschisis (page does not exist)\">myopic macular retinoschisis</a>; visual impairment; blindness. The incidence of VMA is reported as high as 84% for patients with <a href=\"/wiki/Macular_hole\" title=\"Macular hole\">macular hole</a>, 100% for patients with <a href=\"/w/index.php?title=Vitreomacular_traction_syndrome&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Vitreomacular traction syndrome (page does not exist)\">vitreomacular traction syndrome</a>, and 56% in <a href=\"/w/index.php?title=Idiopathic_epimacular_membrane&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Idiopathic epimacular membrane (page does not exist)\">idiopathic epimacular membrane</a>.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Symptomatic_VMA\">Symptomatic VMA</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Vitreomacular_adhesion&amp;action=edit&amp;section=2\" title=\"Edit section: Symptomatic VMA\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Traction caused by VMA is the underlying pathology of an eye disease called symptomatic VMA. There is evidence that symptomatic VMA can contribute to the development of several well-known eye disorders, such as macular hole and macular pucker, that can cause visual impairment, including blindness. It may also be associated with <a href=\"/wiki/Age-related_macular_degeneration\" class=\"mw-redirect\" title=\"Age-related macular degeneration\">age-related macular degeneration</a> (AMD), <a href=\"/wiki/Diabetic_macular_edema\" class=\"mw-redirect\" title=\"Diabetic macular edema\">diabetic macular edema</a> (DME), <a href=\"/wiki/Retinal_vein_occlusion\" class=\"mw-redirect\" title=\"Retinal vein occlusion\">retinal vein occlusion</a>, and <a href=\"/wiki/Diabetic_retinopathy\" title=\"Diabetic retinopathy\">diabetic retinopathy</a> (DR).\n</p>\n<h2><span class=\"mw-headline\" id=\"Diagnosis_and_Treatment_of_Symptomatic_VMA\">Diagnosis and Treatment of Symptomatic VMA</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Vitreomacular_adhesion&amp;action=edit&amp;section=3\" title=\"Edit section: Diagnosis and Treatment of Symptomatic VMA\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Careful eye examination by an <a href=\"/wiki/Ophthalmologist\" class=\"mw-redirect\" title=\"Ophthalmologist\">ophthalmologist</a> or <a href=\"/wiki/Optometrist\" class=\"mw-redirect\" title=\"Optometrist\">optometrist</a> is critical for diagnosing symptomatic VMA. Imaging technologies such as <a href=\"/wiki/Optical_coherence_tomography\" title=\"Optical coherence tomography\">optical coherence tomography</a> (OCT) have significantly improved the accuracy of diagnosing symptomatic VMA.\n</p><p>A new FDA approved drug was released on the market late 2013. <i><b>Jetrea (Brand name) or Ocriplasmin</b></i> (Generic name) is the first drug of its kind used to treat vitreomacular adhension. \nMechanism of Action: Ocriplasmin is a truncated human plasmin with proteolytic activity against protein components of the vitreous body and vitreretinal interface. It dissolves the protein matrix responsible for the vitreomacular adhesion. \nAdverse drug reactions: Decreased vision, potential for lens sublaxation, dyschromatopsia (yellow vision), eye pain, floaters, blurred vision. \nNew Drug comparison Rating gave Jetea a 5 indicating an important advance. \nPreviously, no recommended treatment was available for the patient with mild symptomatic VMA. In symptomatic VMA patients with more significant vision loss, the standard of care is pars plana vitrectomy (PPV), which involves surgically removing the vitreous from the eye, thereby surgically releasing the symptomatic VMA. In other words, vitrectomy induces PVD to release the traction/adhesion on the retina. An estimated 850,000 vitrectomy procedures are performed globally on an annual basis with 250,000 in the United States alone.\n</p><p>A standard PPV procedure can lead to serious complications<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup> including small-gauge PPV.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup> Complications can include <a href=\"/wiki/Retinal_detachment\" title=\"Retinal detachment\">retinal detachment</a>, <a href=\"/wiki/Retinal_tear\" class=\"mw-redirect\" title=\"Retinal tear\">retinal tears</a>, <a href=\"/wiki/Endophthalmitis\" title=\"Endophthalmitis\">endophthalmitis</a>, and postoperative <a href=\"/wiki/Cataract\" title=\"Cataract\">cataract</a> formation. Additionally, PPV may result in incomplete separation, and it may potentially leave a <a href=\"/wiki/Natural_reservoir\" title=\"Natural reservoir\">nidus</a> for <a href=\"/wiki/Vasoactive\" class=\"mw-redirect\" title=\"Vasoactive\">vasoactive</a> and <a href=\"/w/index.php?title=Vasoproliferative&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Vasoproliferative (page does not exist)\">vasoproliferative</a> substances, or it may induce development of <a href=\"/w/index.php?title=Fibrovascular_membrane&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Fibrovascular membrane (page does not exist)\">fibrovascular membranes</a>. As with any invasive surgical procedure, PPV introduces <a href=\"/wiki/Trauma_(medicine)\" class=\"mw-redirect\" title=\"Trauma (medicine)\">trauma</a> to the vitreous and surrounding tissue.<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup><sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup> \n</p><p>There are data showing that nonsurgical induction of PVD using <a href=\"/wiki/Ocriplasmin\" title=\"Ocriplasmin\">ocriplasmin</a> (a <a href=\"/wiki/Recombinant_DNA\" title=\"Recombinant DNA\">recombinant</a> <a href=\"/wiki/Protease\" title=\"Protease\">protease</a> with activity against <a href=\"/wiki/Fibronectin\" title=\"Fibronectin\">fibronectin</a> and <a href=\"/wiki/Laminin\" title=\"Laminin\">laminin</a>)<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup> can offer the benefits of successful PVD while eliminating the risks associated with a surgical procedure, i.e. vitrectomy. <a href=\"/wiki/Pharmacologic\" class=\"mw-redirect\" title=\"Pharmacologic\">Pharmacologic</a> vitreolysis is an improvement over invasive surgery as it induces complete separation, creates a more physiologic state of the vitreomacular interface, prevents the development of fibrovascular membranes, is less traumatic to the vitreous, and is potentially <a href=\"/wiki/Prophylactic\" class=\"mw-redirect\" title=\"Prophylactic\">prophylactic</a>.<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup><sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> As of 2012, <a href=\"/w/index.php?title=ThromboGenics&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"ThromboGenics (page does not exist)\">ThromboGenics</a> is still developing the ocriplasmin biological agent. Ocriplasmin is approved recently under the name Jetrea for use in the <a href=\"/wiki/United_States\" title=\"United States\">United States</a> by the <a href=\"/wiki/US_Food_and_Drug_Administration\" class=\"mw-redirect\" title=\"US Food and Drug Administration\">FDA</a>.view.<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup>\n</p><p>An experimental test of injections of <a href=\"/wiki/Perfluoropropane\" class=\"mw-redirect\" title=\"Perfluoropropane\">perfluoropropane</a> (C<sub>3</sub>F<sub>8</sub>) on 15 symptomatic eyes of 14 patients showed that vitreomacular traction resolved in 6 eyes within 1 month and resolved in 3 more eyes within 6 months.<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Vitreomacular_adhesion&amp;action=edit&amp;section=4\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\">Paolo Carpineto, Luca Di Antonio, Agbeanda Aharrh-Gnama, Vincenzo Ciciarelli, Leonardo Mastropasqua. Diagnosing and Treating Vitreomacular Adhesion. European Ophthalmic Review, 2011,5(1):69-73</span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\">Koerner F, Garweg J. [Diseases of the vitreo-macular interface]. Klin Monbl Augenheilkd. 1999;214(5):305-310.</span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\">Mojana F, Cheng L, Bartsch DU, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146(2):218-227.</span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\">Doft BH, Wisniewski SR, Kelsey SF, Groer-Fitzgerald S; Endophthalmitis Vitrectomy Study Group. Diabetes and postcataract extraction endophthalmitis. Curr Opin Ophthalmol. 2002;13(3):147-151.</span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\">Doft BM, Kelsey SF, Wisniewski SR. Retinal detachment in the endophthalmitis vitrectomy study. Arch Ophthalmol. 2000;118(12):1661-1665.</span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\">Wisniewski SR, Capone A, Kelsey SF, et al. Characteristics after cataract extraction or secondary lens implantation among patients screened for the Endophthalmitis Vitrectomy Study. Ophthalmology. 2000;107(7):1274-1282.</span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\">Gupta OP, Weichel ED, Regillo CD, et al. Postoperative complications associated with 25-gauge pars plana vitrectomy. Ophthalmic Surg Lasers Imaging. 2007;38(4):270\u2013275.</span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\">\nLiu DT, Chan CK, Fan DS, Lam SW, Lam DS, Chan WM. Choroidal folds after 25 gauge transconjunctival sutureless vitrectomy. Eye. 2005;19(7):825\u2013827.</span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\">\nScott IU, Flynn HW Jr, Dev S, et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina. 2008;28(1):138\u2013142.</span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\">\nKunimoto DY, Kaiser RS; Wills Eye Retina Service. Incidence of endophthalmitis after 20- and 25- gauge vitrectomy. Ophthalmology. 2007;114(12):2133\u20132137.</span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\">\nKaiser RS. Complications of sutureless vitrectomy and the findings of the Micro-Surgical Safety Task Force. Paper presented at: Retina Subspecialty Day, Annual Meeting of the American Academy of Ophthalmology; November 7\u20138, 2008; Atlanta, GA.</span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\">de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology. 2009;116(7):1349-1355.</span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\">\nGoldenberg DT, Trese MT. Pharmacologic vitreodynamics and molecular flux. Dev Ophthalmol. 2009;44:31-36.</span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\">Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012 Aug 16;367(7):606-15.</span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\">de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology. 2009;116(7):1349-1355.</span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\">\nGoldenberg DT, Trese MT. Pharmacologic vitreodynamics and molecular flux. Dev Ophthalmol. 2009;44:31-36.</span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://bmctoday.net/retinatoday/2012/05/supplement/article.asp?f=symptomatic-vitreomacular-adhesion\">http://bmctoday.net/retinatoday/2012/05/supplement/article.asp?f=symptomatic-vitreomacular-adhesion</a></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Rodrigues IA; Stangos AN; McHugh DA; Jackson TL (2013). \"Intravitreal injection of expansile perfluoropropane (C<sub>3</sub>F<sub>8</sub>) for the treatment of vitreomacular traction\". <i>American Journal of Ophthalmology</i>. <b>155</b> (2)): 270\u2013276. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.ajo.2012.08.018\">10.1016/j.ajo.2012.08.018</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=American+Journal+of+Ophthalmology&amp;rft.atitle=Intravitreal+injection+of+expansile+perfluoropropane+%28C%3Csub%3E3%3C%2Fsub%3EF%3Csub%3E8%3C%2Fsub%3E%29+for+the+treatment+of+vitreomacular+traction&amp;rft.volume=155&amp;rft.issue=2%29&amp;rft.pages=270-276&amp;rft.date=2013&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ajo.2012.08.018&amp;rft.au=Rodrigues+IA&amp;rft.au=Stangos+AN&amp;rft.au=McHugh+DA&amp;rft.au=Jackson+TL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVitreomacular+adhesion\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n\n<!-- \nNewPP limit report\nParsed by mw2230\nCached time: 20180918071312\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.160 seconds\nReal time usage: 0.235 seconds\nPreprocessor visited node count: 730/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 5180/2097152 bytes\nTemplate argument size: 318/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 8227/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.063/10.000 seconds\nLua memory usage: 2.43 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  190.890      1 -total\n 63.49%  121.202      1 Template:Infobox_disease\n 43.34%   82.723      1 Template:Infobox\n 29.63%   56.564      1 Template:Cite_journal\n  6.05%   11.551      1 Template:Comma_separated_entries\n  3.87%    7.388      2 Template:Main_other\n  0.97%    1.854      1 Template:Template_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:37204201-0!canonical and timestamp 20180918071311 and revision id 735096947\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Infobox_medical_condition"},{"sortkey":"","*":"Eye_surgery"},{"sortkey":"","*":"Eye"},{"sortkey":"","*":"Old_age"},{"sortkey":"","*":"Geriatrics"},{"sortkey":"","*":"Epidemiology"}],"links":[{"ns":0,"exists":"","*":"Age-related macular degeneration"},{"ns":0,"exists":"","*":"Bleeding"},{"ns":0,"exists":"","*":"Brain"},{"ns":0,"exists":"","*":"Cataract"},{"ns":0,"exists":"","*":"Collagen"},{"ns":0,"exists":"","*":"Diabetic macular edema"},{"ns":0,"exists":"","*":"Diabetic retinopathy"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Diseases Database"},{"ns":0,"exists":"","*":"Distorted vision"},{"ns":0,"exists":"","*":"Edema"},{"ns":0,"exists":"","*":"Endophthalmitis"},{"ns":0,"exists":"","*":"Epiretinal membrane"},{"ns":0,"exists":"","*":"Fibronectin"},{"ns":0,"exists":"","*":"Human"},{"ns":0,"exists":"","*":"Human eye"},{"ns":0,"exists":"","*":"Laminin"},{"ns":0,"exists":"","*":"Liquify"},{"ns":0,"exists":"","*":"Macular hole"},{"ns":0,"exists":"","*":"Macular pucker"},{"ns":0,"exists":"","*":"Medical condition"},{"ns":0,"exists":"","*":"Metamorphopsia"},{"ns":0,"exists":"","*":"Natural reservoir"},{"ns":0,"exists":"","*":"Nerve signal"},{"ns":0,"exists":"","*":"Ocriplasmin"},{"ns":0,"exists":"","*":"Ophthalmologist"},{"ns":0,"exists":"","*":"Optic nerve"},{"ns":0,"exists":"","*":"Optical coherence tomography"},{"ns":0,"exists":"","*":"Optometrist"},{"ns":0,"exists":"","*":"Pathologies"},{"ns":0,"exists":"","*":"Perfluoropropane"},{"ns":0,"exists":"","*":"Pharmacologic"},{"ns":0,"exists":"","*":"Posterior vitreous detachment"},{"ns":0,"exists":"","*":"Prophylactic"},{"ns":0,"exists":"","*":"Protease"},{"ns":0,"exists":"","*":"Recombinant DNA"},{"ns":0,"exists":"","*":"Retina"},{"ns":0,"exists":"","*":"Retinal detachment"},{"ns":0,"exists":"","*":"Retinal tear"},{"ns":0,"exists":"","*":"Retinal vein occlusion"},{"ns":0,"exists":"","*":"Standard of care"},{"ns":0,"exists":"","*":"Syneresis (chemistry)"},{"ns":0,"exists":"","*":"Trauma (medicine)"},{"ns":0,"exists":"","*":"US Food and Drug Administration"},{"ns":0,"exists":"","*":"United States"},{"ns":0,"exists":"","*":"Vasoactive"},{"ns":0,"exists":"","*":"Visual processing"},{"ns":0,"exists":"","*":"Vitrectomy"},{"ns":0,"exists":"","*":"Vitreous humour"},{"ns":0,"*":"Vitreomacular traction"},{"ns":0,"*":"Synchisis"},{"ns":0,"*":"Tractional macular oedema"},{"ns":0,"*":"Myopic macular retinoschisis"},{"ns":0,"*":"Vitreomacular traction syndrome"},{"ns":0,"*":"Idiopathic epimacular membrane"},{"ns":0,"*":"Vasoproliferative"},{"ns":0,"*":"Fibrovascular membrane"},{"ns":0,"*":"ThromboGenics"}],"templates":[{"ns":10,"exists":"","*":"Template:Infobox disease"},{"ns":10,"exists":"","*":"Template:Infobox medical condition"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Comma separated entries"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:Separated entries"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Wikidata"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:I18n"},{"ns":828,"*":"Module:Infobox/i18n"},{"ns":828,"exists":"","*":"Module:Wikidata/i18n"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Math"},{"ns":828,"exists":"","*":"Module:ParameterCount"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"}],"images":["Schematic_diagram_of_the_human_eye_en.svg"],"externallinks":["//doi.org/10.1016/j.ajo.2012.08.018","http://bmctoday.net/retinatoday/2012/05/supplement/article.asp?f=symptomatic-vitreomacular-adhesion","http://www.diseasesdatabase.com/ddb35117.htm"],"sections":[{"toclevel":1,"level":"2","line":"Pathology","number":"1","index":"1","fromtitle":"Vitreomacular_adhesion","byteoffset":1301,"anchor":"Pathology"},{"toclevel":1,"level":"2","line":"Symptomatic VMA","number":"2","index":"2","fromtitle":"Vitreomacular_adhesion","byteoffset":3478,"anchor":"Symptomatic_VMA"},{"toclevel":1,"level":"2","line":"Diagnosis and Treatment of Symptomatic VMA","number":"3","index":"3","fromtitle":"Vitreomacular_adhesion","byteoffset":3971,"anchor":"Diagnosis_and_Treatment_of_Symptomatic_VMA"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"4","fromtitle":"Vitreomacular_adhesion","byteoffset":10197,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Vitreomacular adhesion","iwlinks":[{"prefix":"d","url":"https://www.wikidata.org/wiki/Q7937230","*":"d:Q7937230"}],"properties":[{"name":"wikibase_item","*":"Q7937230"}]}}